Introduction:
AstraZeneca is set to invest US$1.5 billion to open a new manufacturing facility for antibody drug conjugates (ADCs) in Singapore.
Features:
This state-of-the-art greenfield facility will be the first to provide end-to-end ADC production, encompassing all stages of the manufacturing process at a commercial scale.
This significant investment highlights biopharmaceutical manufacturing capabilities and talent. It bolsters Singapore's ecosystem, facilitating the development and production of precision medicines, and generates significant employment and economic opportunities.
The multi-step process of manufacturing ADCs involves antibody production, synthesis of the chemotherapy drug and linker, conjugation of the drug-linker to the antibody, and filling the completed ADC substance.
The new facility will be designed to emit zero carbon from its first day of operations commencing design and construction by the end of 2024, with a target for operational readiness by 2029.
Specifications:
Name AstraZeneca
Type New Manufacturing Facility
Budget US$1.5 billion
Year 2024
